Radiotherapeutics For Neuroendocrine Tumors With Perspective Therapeutics' Thijs Spoor

About this episode

Thijs Spoor discusses the resurgence of radiopharmaceuticals and the importance of biodistribution in therapeutic production.

We love to hear from our listeners. Send us a message. On this week's episode of the Business of Biotech, Thijs Spoor, CEO at Perspective Therapeutics, a company developing Pb 212 (lead)-based therapeutics, talks about why radiopharmaceuticals are surging again and why biodistribution is the make-or-break variable when your payload is a radioactive isotope. Thijs discusses the reasons behind Perspective's investment in a proprietary generator for therapeutic production, manufacturing a...

People in this episode

Host: Ben Comer

Guest: Thijs Spoor

Topics covered

• radiotherapeutics
• neuroendocrine tumors
• biopharmaceuticals
• biodistribution
• therapeutic production

Keywords

• radiotherapeutics
• neuroendocrine tumors
• Pb 212
• biodistribution
• Perspective Therapeutics

Mentioned in this episode

Organizations: Perspective Therapeutics

Products: Pb 212, radiopharmaceuticals

More episodes of Business Of Biotech

• The Editors' Roundtable: A Midyear Look At The 2026 Life Sciences Industry · June 8, 2026 · 1h 24m
• Derisking CNS Drug Development With Tortugas Neuroscience's Jeff Jonas, M.D. · June 1, 2026 · 50 min
• Rare Disease Drug Commercialization With Zevra Therapeutics' Neil McFarlane · May 25, 2026 · 55 min
• Scaling Manufacturing For Personalized Cell Therapies With Cellino's Marinna Madrid, Ph.D. · May 18, 2026 · 51 min
• Building A New Antibody Discovery Platform With Infinimmune's Wyatt McDonnell, Ph.D. · May 11, 2026 · 54 min
• From Partnered ASO Therapies To A Wholly-Owned Pipeline With Ionis's Brett Monia, Ph.D. · May 4, 2026 · 56 min